A meta‐analysis of all relevant published randomized, controlled trials (RCTs) was performed to compare the efficiency and safety of lapatinib and trastuzumab, alone or in combination, administered with neoadjuvant chemotherapy in patients with HER2‐positive breast cancer. Here, ERBB2 is linked to breast cancer.